NASDAQ: SILO - Silo Pharma, Inc.

Rentabilidade por seis meses: -50.49%
Setor: Healthcare

Cronograma de promoção Silo Pharma, Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa

Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. The company's developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders.

Mais detalhes
The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

Цена ао 1.94
Выручка 4.1E-5
EBITDA -0.000902
Число акций ао 0.00308 млрд
P/E 3.5
P/S 219.82
P/BV -389.57
EV/EBITDA -9.83
Сайт https://silopharma.com
Валюта usd
IPO date 2014-05-13
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Alteração de preço por dia: -3.77% (1.06)
Alteração de preço por semana: -3.77% (1.06)
Alteração de preço por mês: -9.73% (1.13)
Alteração de preço em 3 meses: +5.92% (0.963)
Mudança de preço em seis meses: -50.49% (2.06)
Mudança de preço por ano: -36.25% (1.6)
Mudança de preço em 3 anos: +466.67% (0.18)
Mudança de preço em 5 anos: +12 339.02% (0.0082)
Mudança de preço desde o início do ano: -35.85% (1.59)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 68.34 1
P/BV 0.7978 9
P/E 0 0
EV/EBITDA -0.364 0
Total: 4.63

Eficiência

Nome Significado Nota
ROA, % -47.77 0
ROE, % -59.91 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA 0 10
Total: 9.8

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 75.86 8
Rentabilidade Ebitda, % 327.45 10
Rentabilidade EPS, % -46.12 0
Total: 7.6
Mais detalhes

Instituições Volume Compartilhar, %
Financial Advocates Investment Management 62807 0.06
UBS Group AG 32843 0.03
Vanguard Group Inc 16334 0.02
Geode Capital Management, LLC 16179 0.02
TWO SIGMA SECURITIES, LLC 12788 0.01
State Street Corporation 12500 0.01
Tower Research Capital LLC (TRC) 7007 0.01
Westside Investment Management, Inc. 94 0
FWL INVESTMENT MANAGEMENT, LLC 80 0
Wells Fargo & Company 20 0

ETF Compartilhar, % Rentabilidade para o ano, % Dividendos, %
Avantis Emerging Markets Equity ETF 0.00003 11.542669584245 3.60513
Dimensional Emerging Markets Core Equity 2 ETF 0.00246 15.961857379768 3.34087
Dimensional Emerging Markets Value ETF 0.00004 17.066115702479 4.19508
SPDR S&P Emerging Markets Small Cap ETF 0.01392 9.4592150479291 3.03583
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund 0.00179 12.462475271255 3.59676



Supervisor Cargo Pagamento Ano de nascimento
Mr. Eric Weisblum Chairman, President & CEO 569.01k 1970 (54 ano)
Mr. Daniel E. Ryweck Chief Financial Officer 62.69k 1965 (59 anos)
Dr. James S. Kuo M.B.A., M.D. Vice President of Research & Development N/A 1965 (59 anos)

Endereço: United States, Englewood Cliffs. NJ, 560 Sylvan Avenue - abrir no Google Maps, abrir mapas Yandex
Site: https://silopharma.com